Palo Alto Investors

VYNE Therapeutics Inc. is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for dermatological conditions. It offers AMZEEQ, a topical minocycline treatment for non-nodular moderate-to-severe acne vulgaris in patients aged 9 and older. The company is advancing its pipeline with FMX103, currently in Phase III clinical trials for moderate-to-severe papulopustular rosacea in adults, and FCD105, a topical combination foam under investigation in Phase II trials for moderate-to-severe acne vulgaris. Additionally, VYNE is developing Serlopitant, an oral NK1 receptor antagonist aimed at addressing pruritus associated with prurigo nodularis, as well as exploring therapies for other immuno-inflammatory conditions. Formerly known as Menlo Therapeutics Inc., the company rebranded in September 2020 and is headquartered in Bridgewater, New Jersey.

Gossamer Bio is a clinical-stage biopharmaceutical company based in San Diego that specializes in the discovery, development, and commercialization of innovative therapeutic products targeting significant unmet medical needs. Founded by former executives from Receptos, the company focuses on areas such as immunology, inflammation, fibrosis, and oncology. Its pipeline includes several promising candidates: Seralutinib, aimed at addressing pulmonary arterial hypertension; GB004, for inflammatory bowel disease; GB1275, targeting various oncology indications; and GB001, designed for moderate-to-severe eosinophilic asthma. Gossamer Bio's strategy involves leveraging a rich in-licensing environment to enhance its therapeutic offerings, supported by a team recognized for their successful track record in drug development.

Peak Bio is a clinical-stage biopharmaceutical company dedicated to the development of therapeutics aimed at addressing unmet medical needs in oncology, inflammation, and rare diseases. The company is focused on creating innovative drug solutions to improve patient outcomes in these therapeutic areas. By prioritizing the development of new treatments, Peak Bio seeks to make a significant impact on the healthcare landscape, particularly for conditions that currently lack effective therapies.

Gilgamesh Pharmaceuticals, Inc. is a preclinical biotechnology company based in New York, focused on developing innovative psychotropic drugs to address mental health issues. Founded in 2019, the company specializes in creating novel compounds that enhance the benefits of traditional psychedelics, improving parameters such as safety, tolerability, duration, and efficacy. Gilgamesh targets a range of neuropsychiatric conditions, including depression, anxiety, substance use disorders, and stress-related issues. With the growing global mental health crisis, the company aims to accelerate the development of new treatments that meet the urgent need for effective solutions in mental health care, leveraging its expertise in medicinal chemistry and drug development.

NewLeaf Symbiotics, Inc. is an agriculture technology company based in Saint Louis, Missouri, dedicated to the research, development, and commercialization of beneficial symbiotic bacteria aimed at enhancing plant health and increasing crop yields. The company focuses on naturally occurring bacteria, particularly pink pigmented facultative methylotrophs, which are utilized across various agricultural sectors, including row crops, vegetables, fruits, and ornamental plants. NewLeaf Symbiotics conducts extensive laboratory, greenhouse, and field trials to validate the effectiveness of its products, providing farmers with sustainable solutions to combat plant diseases and improve agricultural productivity. Originally founded as TrophoMax, LLC in 2011, the company rebranded in July 2012 to better reflect its mission and objectives in the agricultural biotechnology space.

NeXeption, LLC is a biopharmaceutical management company that brings together product opportunities, management expertise and the necessary funding to reach compelling partnership milestones. The NeXeption management team has a proven track record in raising capital, operating development stage companies and forming strategic partnerships to advance products for the benefit of patients.

Alimera Sciences, Inc. is a pharmaceutical company focused on the research, development, and commercialization of prescription ophthalmic pharmaceuticals, particularly targeting diseases affecting the retina. The company is best known for its product ILUVIEN, an intravitreal implant designed for the treatment of diabetic macular edema (DME), a serious condition that can lead to vision loss in individuals with diabetes. ILUVIEN is administered through a non-surgical procedure, delivering a continuous microdose of fluocinolone acetonide directly to the eye, thereby reducing the need for frequent injections. Alimera Sciences also collaborates with EyePoint Pharmaceuticals for the development of additional corticosteroid delivery technologies aimed at treating various eye conditions. The company markets its products through direct sales and distribution channels, serving physician offices, pharmacies, and hospitals. Founded in 2003, Alimera Sciences is headquartered in Alpharetta, Georgia, and operates internationally, including in markets such as Germany, the United Kingdom, China, and the Middle East.

Ceptaris Therapeutics, Inc. is a privately held specialty pharmaceutical company focused on developing innovative treatments for rare cancers. The company is working on a proprietary gel formulation of mechlorethamine hydrochloride aimed at treating early-stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL). If successful, this investigational drug would be the first topical mechlorethamine product available to alleviate the signs and symptoms associated with this condition. In addition to its primary focus on CTCL, Ceptaris is also advancing YT-1006, an NMDA antagonist designed for treating neuropathic pain while mitigating side effects through a unique stereochemistry approach.

Ceptaris Therapeutics, Inc. is a privately held specialty pharmaceutical company focused on developing innovative treatments for rare cancers. The company is working on a proprietary gel formulation of mechlorethamine hydrochloride aimed at treating early-stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL). If successful, this investigational drug would be the first topical mechlorethamine product available to alleviate the signs and symptoms associated with this condition. In addition to its primary focus on CTCL, Ceptaris is also advancing YT-1006, an NMDA antagonist designed for treating neuropathic pain while mitigating side effects through a unique stereochemistry approach.

Revance Therapeutics, Inc. is a biotechnology company that specializes in the development, manufacture, and commercialization of neuromodulators for aesthetic and therapeutic indications. The company's lead product, DaxibotulinumtoxinA for injection (DAXI), is undergoing various stages of clinical trials for treatments including glabellar lines, cervical dystonia, adult upper limb spasticity, plantar fasciitis, and chronic migraine. Revance is also advancing DAXI for aesthetic applications such as forehead lines and lateral canthal lines. Additionally, the company is developing DaxibotulinumtoxinA Topical for both therapeutic and aesthetic uses, alongside a biosimilar formulation akin to BOTOX. Revance has established collaboration agreements for the development and commercialization of its biosimilar products. Founded in 1999 and headquartered in Newark, California, Revance was previously known as Essentia Biosystems, Inc., having rebranded in 2005. The company is committed to enhancing its portfolio in dermatology and aesthetic medicine, including a range of dermal fillers and a platform for aesthetic services.

Fisker, Inc. is an American company headquartered in Manhattan Beach, California, that designs and manufactures electric vehicles and mobility solutions. The company focuses on creating eco-friendly vehicles that evoke emotional connections, aligning with its mission to promote a sustainable future for all. Fisker aims to position itself as an e-mobility service provider, emphasizing the development of innovative electric vehicles that are both environmentally friendly and desirable to consumers. Historically, Fisker Automotive gained recognition for the Fisker Karma, which was among the first luxury plug-in hybrid electric vehicles, but production was halted due to financial challenges. Today, Fisker, Inc. continues to pursue advancements in electric mobility, striving to revolutionize the automotive industry with its commitment to sustainability and design.

Revance Therapeutics, Inc. is a biotechnology company that specializes in the development, manufacture, and commercialization of neuromodulators for aesthetic and therapeutic indications. The company's lead product, DaxibotulinumtoxinA for injection (DAXI), is undergoing various stages of clinical trials for treatments including glabellar lines, cervical dystonia, adult upper limb spasticity, plantar fasciitis, and chronic migraine. Revance is also advancing DAXI for aesthetic applications such as forehead lines and lateral canthal lines. Additionally, the company is developing DaxibotulinumtoxinA Topical for both therapeutic and aesthetic uses, alongside a biosimilar formulation akin to BOTOX. Revance has established collaboration agreements for the development and commercialization of its biosimilar products. Founded in 1999 and headquartered in Newark, California, Revance was previously known as Essentia Biosystems, Inc., having rebranded in 2005. The company is committed to enhancing its portfolio in dermatology and aesthetic medicine, including a range of dermal fillers and a platform for aesthetic services.

Fisker, Inc. is an American company headquartered in Manhattan Beach, California, that designs and manufactures electric vehicles and mobility solutions. The company focuses on creating eco-friendly vehicles that evoke emotional connections, aligning with its mission to promote a sustainable future for all. Fisker aims to position itself as an e-mobility service provider, emphasizing the development of innovative electric vehicles that are both environmentally friendly and desirable to consumers. Historically, Fisker Automotive gained recognition for the Fisker Karma, which was among the first luxury plug-in hybrid electric vehicles, but production was halted due to financial challenges. Today, Fisker, Inc. continues to pursue advancements in electric mobility, striving to revolutionize the automotive industry with its commitment to sustainability and design.

Fisker, Inc. is an American company headquartered in Manhattan Beach, California, that designs and manufactures electric vehicles and mobility solutions. The company focuses on creating eco-friendly vehicles that evoke emotional connections, aligning with its mission to promote a sustainable future for all. Fisker aims to position itself as an e-mobility service provider, emphasizing the development of innovative electric vehicles that are both environmentally friendly and desirable to consumers. Historically, Fisker Automotive gained recognition for the Fisker Karma, which was among the first luxury plug-in hybrid electric vehicles, but production was halted due to financial challenges. Today, Fisker, Inc. continues to pursue advancements in electric mobility, striving to revolutionize the automotive industry with its commitment to sustainability and design.

Revance Therapeutics, Inc. is a biotechnology company that specializes in the development, manufacture, and commercialization of neuromodulators for aesthetic and therapeutic indications. The company's lead product, DaxibotulinumtoxinA for injection (DAXI), is undergoing various stages of clinical trials for treatments including glabellar lines, cervical dystonia, adult upper limb spasticity, plantar fasciitis, and chronic migraine. Revance is also advancing DAXI for aesthetic applications such as forehead lines and lateral canthal lines. Additionally, the company is developing DaxibotulinumtoxinA Topical for both therapeutic and aesthetic uses, alongside a biosimilar formulation akin to BOTOX. Revance has established collaboration agreements for the development and commercialization of its biosimilar products. Founded in 1999 and headquartered in Newark, California, Revance was previously known as Essentia Biosystems, Inc., having rebranded in 2005. The company is committed to enhancing its portfolio in dermatology and aesthetic medicine, including a range of dermal fillers and a platform for aesthetic services.

Fisker, Inc. is an American company headquartered in Manhattan Beach, California, that designs and manufactures electric vehicles and mobility solutions. The company focuses on creating eco-friendly vehicles that evoke emotional connections, aligning with its mission to promote a sustainable future for all. Fisker aims to position itself as an e-mobility service provider, emphasizing the development of innovative electric vehicles that are both environmentally friendly and desirable to consumers. Historically, Fisker Automotive gained recognition for the Fisker Karma, which was among the first luxury plug-in hybrid electric vehicles, but production was halted due to financial challenges. Today, Fisker, Inc. continues to pursue advancements in electric mobility, striving to revolutionize the automotive industry with its commitment to sustainability and design.

Ceptaris Therapeutics, Inc. is a privately held specialty pharmaceutical company focused on developing innovative treatments for rare cancers. The company is working on a proprietary gel formulation of mechlorethamine hydrochloride aimed at treating early-stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL). If successful, this investigational drug would be the first topical mechlorethamine product available to alleviate the signs and symptoms associated with this condition. In addition to its primary focus on CTCL, Ceptaris is also advancing YT-1006, an NMDA antagonist designed for treating neuropathic pain while mitigating side effects through a unique stereochemistry approach.

Gemfire Corporation, founded in 1995, operates in the field of high-performance telecom and specialty components, utilizing advanced planar semiconductor processing technology. The company develops innovative optical solutions tailored for system integrators, leveraging its Gemfire PhotonICTM technology platform to enable wafer-scale processing. This approach allows for the efficient production of various optical components, including Athermal and standard Arrayed Waveguide Gratings (AWGs), Tunable Optical Devices (TODCs), Variable Optical Attenuators (VOAs), and Wavelength Multiplexers (VMUXs). Gemfire's primary operations are based in Livingston, Scotland, with additional aerospace support and telecom manufacturing facilities located in Fremont, California.

Paracor Medical is a medical device company established in 1999 that specializes in developing innovative, technology-driven solutions for the treatment of heart failure. The company focuses on creating alternatives to traditional open chest surgery, aiming to alleviate the burden on patients with failing heart muscles. By employing a mechanical approach, Paracor Medical seeks to enhance the effectiveness of heart failure treatment while minimizing the invasiveness of procedures.

Amicus Therapeutics, Inc. is a biotechnology company dedicated to the discovery, development, and commercialization of therapies for rare and orphan diseases. Founded in 2002 and headquartered in Cranbury, New Jersey, the company focuses on developing innovative treatments, including Galafold, an orally administered pharmacological chaperone for Fabry disease. Amicus is also advancing its pipeline with a Phase 3 clinical study of AT-GAA for Pompe disease. The company's research includes a range of first-in-class small molecules designed to treat lysosomal storage diseases by stabilizing misfolded enzymes in patients. This therapeutic approach potentially enhances the effectiveness of enzyme replacement therapies. Amicus Therapeutics has established collaborations with institutions such as Nationwide Children's Hospital and the University of Pennsylvania to further its research and development efforts.

SkyPilot Networks is a prominent provider of carrier-class broadband wireless equipment, catering to service providers, municipalities, and public safety agencies. The company specializes in enabling the rapid deployment of cost-effective network services, including last-mile Internet access, voice over IP, Wi-Fi hotspots, and video surveillance. Utilizing a patented multi-hop point-to-multipoint architecture, SkyPilot's solutions synchronize high-gain directional antennas to enhance reach, reduce interference, and optimize spectral efficiency. This approach results in a highly scalable and reliable broadband wireless network that simplifies design and increases deployment flexibility while significantly lowering equipment and operating costs. SkyPilot's products, such as the SkyPilot Connector Mini and Pro for long-range connectivity, as well as the SkyPilot EMS for network management, support a wide range of wireless applications. The company has successfully delivered its solutions to customers in over 50 countries and is headquartered in Santa Clara, California.

Mercator MedSystems, Inc. is a medical technology company based in Emeryville, California, specializing in catheter-guided microfluid injection systems for the targeted delivery of therapeutic agents across blood vessels. The company offers innovative products, including the Cricket and Bullfrog micro-infusion catheters, which facilitate the direct injection of therapies into deep tissues, thereby enhancing treatment efficacy while minimizing systemic exposure. Mercator's technology addresses various medical conditions, including blood vessel restenosis, peripheral artery disease, and neointimal hyperplasia associated with dialysis access failure. Their micro-infusion devices are designed to deliver drugs, genes, and cells without compromising viability or potency. The company's applications extend to treatments for plaque stabilization, anti-tumor therapies, and regenerative medicine. Founded in 1999, Mercator MedSystems aims to improve patient outcomes through precise and effective therapeutic delivery, ultimately advancing the field of vascular disease management and oncology.

FlowMedica is a medical device company specializing in intravascular systems for Targeted Renal Therapy. The company develops innovative solutions aimed at addressing kidney dysfunction associated with cardiovascular disease, cancer, and surgical procedures. Its flagship product, the Benephit CV Infusion System, enables physicians to deliver therapeutic agents directly into the renal arteries through an infusion catheter, facilitating simultaneous coronary procedures via a single access point in the femoral artery. Additionally, the Benephit XTMini Infusion System caters to patients with smaller vascular anatomies by allowing bilateral infusion to the kidneys. FlowMedica's devices present a precise alternative to traditional systemic intravenous infusion methods, enabling surgeons to administer treatments directly and accurately.

Amicus Therapeutics, Inc. is a biotechnology company dedicated to the discovery, development, and commercialization of therapies for rare and orphan diseases. Founded in 2002 and headquartered in Cranbury, New Jersey, the company focuses on developing innovative treatments, including Galafold, an orally administered pharmacological chaperone for Fabry disease. Amicus is also advancing its pipeline with a Phase 3 clinical study of AT-GAA for Pompe disease. The company's research includes a range of first-in-class small molecules designed to treat lysosomal storage diseases by stabilizing misfolded enzymes in patients. This therapeutic approach potentially enhances the effectiveness of enzyme replacement therapies. Amicus Therapeutics has established collaborations with institutions such as Nationwide Children's Hospital and the University of Pennsylvania to further its research and development efforts.

Deem, Inc. is a technology company specializing in Commerce-as-a-Service (CaaS) solutions tailored for the business travel industry. Founded in 1999 and headquartered in San Francisco, California, Deem offers a comprehensive cloud-based suite of applications that streamline travel, expense management, and purchasing for companies. Its platform empowers organizations to manage travel bookings for flights, hotels, and ground transportation while ensuring compliance with corporate spending policies. Additionally, Deem enables merchants to effectively promote and sell their products and services through various channels, enhancing customer engagement with options such as card-linked offers and corporate discounts. The company's focus is on simplifying business travel for employees, reducing costs for employers, and creating profitable opportunities for service providers. Deem operates as a subsidiary of Enterprise Holdings, Inc.

SkyPilot Networks is a prominent provider of carrier-class broadband wireless equipment, catering to service providers, municipalities, and public safety agencies. The company specializes in enabling the rapid deployment of cost-effective network services, including last-mile Internet access, voice over IP, Wi-Fi hotspots, and video surveillance. Utilizing a patented multi-hop point-to-multipoint architecture, SkyPilot's solutions synchronize high-gain directional antennas to enhance reach, reduce interference, and optimize spectral efficiency. This approach results in a highly scalable and reliable broadband wireless network that simplifies design and increases deployment flexibility while significantly lowering equipment and operating costs. SkyPilot's products, such as the SkyPilot Connector Mini and Pro for long-range connectivity, as well as the SkyPilot EMS for network management, support a wide range of wireless applications. The company has successfully delivered its solutions to customers in over 50 countries and is headquartered in Santa Clara, California.

Talima Therapeutics is an emerging drug delivery company dedicated to the development of novel products that increase patient choice and improve quality of life. With a unique approach to therapy, we design customized drug-delivery systems that optimize the local therapeutic performance and reduce the undesired systemic side effects enabling us to address unmet needs or underserved markets. We foster a collaborative environment and strive for excellence internally and with our partners. Our lead product is currently in Phase I/II clinical testing for the treatment of onychomycosis, a fungal disease of the nails and we are in the process of planning its pivotal trials.

LuMend Inc. designs, develops, manufactures and markets medical devices intended to enable physicians to safely, predictably and cost effectively cross Chronic Total Occlusions (CTO) in the coronary vasculature, allowing subsequent conventional guide wire placement across target stenotic lesions. The company was founded in 1996 by two pioneering interventional cardiologists, John Simpson, PhD, MD, and Matthew Selmon, MD.

Labcyte Inc., founded in 2000 and based in San Jose, California, specializes in developing acoustic droplet ejection (ADE) technology for various applications in the life sciences. The company's innovative approach uses focused beams of acoustic energy to precisely dispense nanoliter-scale droplets of fluid from one plate to another, enabling high accuracy at low volumes and reducing consumables costs. Labcyte's products include automation systems, laboratory workstations, and control software, which are utilized in drug discovery, genomics research, cancer research, and personalized medicine. The company operates as a subsidiary of Beckman Coulter, Inc., with additional offices across multiple countries including Canada, the United Kingdom, Australia, India, South Korea, China, Hong Kong, Japan, Singapore, and Taiwan.

SkyPilot Networks is a prominent provider of carrier-class broadband wireless equipment, catering to service providers, municipalities, and public safety agencies. The company specializes in enabling the rapid deployment of cost-effective network services, including last-mile Internet access, voice over IP, Wi-Fi hotspots, and video surveillance. Utilizing a patented multi-hop point-to-multipoint architecture, SkyPilot's solutions synchronize high-gain directional antennas to enhance reach, reduce interference, and optimize spectral efficiency. This approach results in a highly scalable and reliable broadband wireless network that simplifies design and increases deployment flexibility while significantly lowering equipment and operating costs. SkyPilot's products, such as the SkyPilot Connector Mini and Pro for long-range connectivity, as well as the SkyPilot EMS for network management, support a wide range of wireless applications. The company has successfully delivered its solutions to customers in over 50 countries and is headquartered in Santa Clara, California.

Speedera Networks, Inc., founded in 1999 and based in Santa Clara, California, offered distributed application hosting and content delivery services to organizations across various industries and government sectors. The company's suite of on-demand services addressed key challenges such as performance, scalability, availability, and security for distributed applications and websites. Speedera Networks was acquired by Akamai Technologies Inc. in June 2005.

Labcyte Inc., founded in 2000 and based in San Jose, California, specializes in developing acoustic droplet ejection (ADE) technology for various applications in the life sciences. The company's innovative approach uses focused beams of acoustic energy to precisely dispense nanoliter-scale droplets of fluid from one plate to another, enabling high accuracy at low volumes and reducing consumables costs. Labcyte's products include automation systems, laboratory workstations, and control software, which are utilized in drug discovery, genomics research, cancer research, and personalized medicine. The company operates as a subsidiary of Beckman Coulter, Inc., with additional offices across multiple countries including Canada, the United Kingdom, Australia, India, South Korea, China, Hong Kong, Japan, Singapore, and Taiwan.

Conductus is a company that specializes in superconducting wire technology, specifically designed for the development of superconductor electrical devices across various applications. Its flagship product, Conductus®, is a high current carrying conductor that significantly enhances performance compared to traditional copper and aluminum wires, offering higher power density, reduced size, and substantial cost advantages. The wire is produced using a proprietary deposition process known as RCE-CDR. Additionally, Conductus focuses on providing electronic components and systems utilizing high-temperature superconductors for the global telecommunications market, developing devices based on thin-film technology with yttrium barium copper oxide to support various communication standards, including TDMA, CDMA, GSM, and analog base stations.